- CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER
-
The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I):, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6', R7, R7', R8, R9, R9', R10, R11, R12, and n are described herein.
- -
-
Page/Page column 317-318
(2020/06/19)
-
- Endothelin antagonists
-
A compound of the formula (I): or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
- -
-
-
- Use of low-volatility pyrazole derivatives having hydrophilic groups as nitrification inhibitors
-
The present invention provides pyrazole compounds which are useful as nitrification inhibitors.
- -
-
-
- Novel Parham-type Cycloacylations of 1H-Pyrazole-1-alkanoic Acids
-
Exposure of 1H-pyrazole-1-alkanoic acids to two equivalents of n-butyllithium affords the corresponding cyclic ketones via a Parham-type cyclization process. Although yields are modest, this procedure represents a simple and direct intramolecular acylation of a non-nucleophilic pyrazole carbon.
- Larsen, Scott D.
-
p. 1013 - 1014
(2007/10/03)
-